Real-World data mimics heart trial for diabetes drugs

NCT ID NCT07088718

Completed Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether healthcare claims data can predict the results of a major heart trial (SURPASS-CVOT) comparing two diabetes drugs, tirzepatide and dulaglutide. Researchers analyzed records from over 44,000 people with type 2 diabetes and heart disease to see if real-world data could reliably mimic the trial's findings. The goal is to understand when real-world data can be trusted for clinical research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide and dulaglutide
What this could lead to: If successful, this could show that analyzing real-world patient data can reliably predict the outcomes of large clinical trials, potentially speeding up future research.
What could go wrong: This is an observational study using existing data, not a controlled experiment. Results may not perfectly match the original trial due to differences in patient populations or data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR (CV) RISK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR (CV) RISK MAJOR ADVERSE CARDIAC EVENTS TYPE 2 DIABETES

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.